More specifically, the antibody component of ADCs selectively binds to a biomarker/protein (such as HER2) on the surface of the cancer cells, and the covalently bound cytotoxic agent is subsequently released, leading to cell death [57] (Figure 1B, Table 1). The gene discussed is ERBB2; the disease is cancer.